Dr. Dimitrova is pharmaceutical industry executive with 20 years’ wide-ranging clinical and scientific experience. Her experiences include clinical practice in various healthcare settings in US and EU and pharmaceutical industry experience in medical safety, drug development, and regulatory science. She is currently serving as the Global Head of Pharmacovigilance Evaluation and Reporting at Janssen Pharmaceutical, Companies of Johnson and Johnson. Her primary responsibility is to provide overall strategic direction to 40+ scientists and physicians accountable for Janssen’s pharmaceutical products safety assessment and reporting globally. Prior to her current role she was responsible for directing the early clinical development at Pfizer, leading medical surveillance team that championed regulatory approvals for several new medicines for treatment of Hepatitis C at BMS and establishing the medical Risk Management Center of Excellence for Janssen Pharmaceutical. Dr. Dimitrova began her career serving as a hospital physician delivering patient care at Capital Health System in NJ, and initiated her research experience as postdoctoral fellow in immuno-virology at Temple University in Philadelphia. Dr. Dimitrova has authored numerous publications, including original articles, book chapters, and abstracts spanning her work in clinical and academic institutions. She is board certified by the American Board of Internal. She is a member of the American College of Physicians, American Medical Association, and New York Academy of Science.